United Network for Organ Sharing

United Network for Organ Sharing is a national transplant-network institution whose registry evidence helps organize the debate over organ scarcity, hepatitis C virus infection, and kidney transplantation. In the book’s account, its importance lies less in a single clinical intervention than in the way its data connect waiting-list time, donor and recipient characteristics, transplantation decisions, patient survival, and graft outcomes. The network’s analyses expose both the risks attached to hepatitis C virus-positive donor kidneys and the cost of refusing organs that could benefit carefully selected recipients.

Institutional Setting and Transplant Shortage

United Network for Organ Sharing appears within a global system in which transplantation benefits about 100,000 patients each year but available organs remain far below demand. At the end of 2009, approximately 63,000 people were on an organ waiting list in the European Union while only 28,000 transplant procedures were performed during that year. The United States faced a comparable imbalance: almost 111,000 people were registered on the waiting list in May 2011, against roughly 28,000 procedures annually. This shortage means that many patients deteriorate or die while waiting, and it has encouraged the use of expanded-criteria and non-standard-risk donors, including donors with positive hepatitis C virus serology.

The network therefore operates in a setting where refusing a donor organ is not a neutral act. Kidneys from hepatitis C virus-positive donors may transmit infection, and many centers decline them, while some countries impose technical or legal restrictions on their use. At the same time, declining these organs can lengthen waiting times for patients already facing end-stage renal disease. United Network for Organ Sharing data became consequential precisely because they allowed clinicians and policymakers to compare these competing risks at population scale rather than relying only on local center experience.

Registry Evidence on Donor-Positive Kidneys

Registry analyses using United Network for Organ Sharing data produced results that initially appeared unfavorable to hepatitis C virus-positive donor kidneys. In one United States registry analysis, recipients of kidneys from hepatitis C virus-positive donors had decreased patient survival compared with recipients of kidneys from hepatitis C virus-negative donors, regardless of the recipient’s own hepatitis C virus serology; the difference became apparent about two years after transplantation. The higher incidence of posttransplant diabetes mellitus among recipients of hepatitis C virus-positive kidneys was proposed as a possible intermediate complication contributing to the later increase in mortality. These findings led investigators to recommend caution and complete information for potential recipients.

The registry results also revealed how strongly selection could shape apparent donor effects. Recipients of hepatitis C virus-positive kidneys often had a worse baseline clinical and immunological situation than recipients of hepatitis C virus-negative kidneys. They were more likely to be older, to be African American, and to have dialysis-access complications; the allocation system also lacked a consistently applied policy for using hepatitis C virus-positive organs. In addition, the studies did not always record whether recipients had detectable hepatitis C virus RNA at transplantation. These imbalances made it difficult to treat donor serology as an isolated cause of later outcomes.

United Network for Organ Sharing nevertheless identified a substantial benefit for hepatitis C virus-positive recipients who received hepatitis C virus-positive kidneys. Such recipients waited 310 fewer days than the average waiting time at their transplant center and 395 fewer days than comparable recipients at the same center who waited for hepatitis C virus-negative kidneys. Receiving a kidney from a hepatitis C virus-positive donor was independently associated with better survival than remaining on the waiting list, with an adjusted hazard ratio of 0.76 and a 95% confidence interval of 0.60 to 0.96. The registry thus transformed the issue from a simple prohibition into a time-sensitive risk trade-off: an organ carrying an infectious risk could also reduce the dangers of prolonged dialysis and waiting.

Relation to Broader Transplant Outcomes

The network’s evidence is interpreted alongside broader studies showing that kidney transplantation remains preferable to continued dialysis for most hepatitis C virus-infected patients with end-stage renal disease, provided that advanced liver injury is not present. Although hepatitis C virus-positive kidney recipients may have worse long-term patient and graft survival than hepatitis C virus-negative recipients, transplantation still confers a survival advantage over remaining on the waiting list. One study found a relative risk of death of 0.31 for hepatitis C virus-positive patients receiving a transplant during the period seven to forty-eight months after transplantation. Another time-dependent analysis found an early posttransplant hazard ratio of 2.51 during the first six months, followed by a hazard ratio of 0.32 from seven through eighty-four months.

The same tension appears in graft outcomes. A large United Network for Organ Sharing study found a trend toward worse death-censored graft survival in hepatitis C virus-positive recipients as early as three years after transplantation. Other studies, however, found no significant graft-survival difference after adjustment or during shorter follow-up. Across the literature, reported graft loss has been associated with glomerulonephritis and chronic allograft nephropathy, while differences in immunosuppressive regimens, the severity and duration of hepatitis C virus infection, liver histology, and comorbidities may account for discordant findings. The registry therefore supplies essential comparative evidence but does not erase the clinical distinctions among donor status, recipient status, active viremia, liver damage, and immunosuppressive exposure.

Data, Allocation, and Clinical Judgment

The network’s significance is ultimately organizational as well as statistical. Transplantation decisions require screening for anti-hepatitis C virus antibodies and active viremia, assessment of liver injury, and careful consideration of whether a patient has compensated or decompensated cirrhosis. Patients with established or decompensated cirrhosis should be referred for consideration of simultaneous liver-kidney transplantation, while a percutaneous liver biopsy remains the most reliable method for staging liver disease in hepatitis C virus-infected kidney-transplant candidates.

The evidence also bears on the allocation of organs that might otherwise be discarded. Treatment before transplantation can produce a sustained virologic response, but interferon-based therapy has adverse effects, may fail, is prolonged and costly, and can require exclusion from the waiting list during treatment. Some hepatitis C virus RNA-positive patients will refuse treatment, withdraw from it, fail to respond, or be unsuitable for it. For these patients, transplantation may still be more favorable than remaining on dialysis, and a hepatitis C virus-positive kidney may offer the additional advantage of reducing waiting time.

By documenting both delayed hazards and immediate survival benefits, United Network for Organ Sharing makes visible the institutional logic behind selective acceptance of hepatitis C virus-positive kidneys. Its data do not support indiscriminate transplantation, but they challenge blanket refusal: donor seropositivity was not independently associated with death or graft loss in a long-term Spanish comparison of hepatitis C virus-positive recipients, and the broader evidence showed that carefully informed allocation could convert surplus organs into life-saving opportunities. The network’s enduring role is therefore to provide the comparative structure through which scarcity, infection risk, waiting-list mortality, and recipient choice can be weighed together.